DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)

Information source: Tuscaloosa Research & Education Advancement Corporation
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: PTSD

Intervention: topiramate (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Tuscaloosa Research & Education Advancement Corporation

Official(s) and/or principal investigator(s):
Lori L Davis, MD, Principal Investigator, Affiliation: Tuscaloosa VA Medical Center


To study the potential therapeutic effects of topiramate (Topamax) in the treatment of PTSD.

Clinical Details

Official title: Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Potential therapeutic effects of topiramate (Topamax) in the treatment of PTSD as noted in the change of the 17-item total severity score of the Clinician-Administered PTSD scale (CAPS) from baseline to the last visit of Double-Blind Phase (8-weeks)

Secondary outcome: Changes from baseline to the last visit in Double-Blind Phase for HAM-A, MADRS, and TOP-8 Scale, Clinical Global Impression (CGI)scales, and Davidson Trauma Scale (DTS). Each scale will be analyzed as described above for the primary efficacy variable.

Detailed description: This is a twelve-week randomized, double blind, placebo controlled trial of topiramate for 40 patients with PTSD. Diagnoses are made by Structured Clinical Interview for DSM-IV (SCID). Symptom severity is measured with the Clinician Administered PTSD Scale (CAPS), Davidson Trauma Scale (DTS), Treatment Outcome PTSD (TOP-8), Clinical Global Impressions (CGI), and the Hamilton Rating Scales for Depression and Anxiety (HAM-D and HAM-A). The Clinician Administered PTSD Scale (CAPS) is the primary outcome measure. Subjects will read and sign informed consent prior to beginning any study procedures. Subjects who meet inclusion/exclusion criteria will be randomized 1: 1 (Topiramate : placebo) to study medication. Study medication is initiated at one tablet daily (25mg topiramate or placebo) and medication will be increased by 25-100mg (1 tablet) increments every 7 days, as tolerated, until a maximum benefit is achieved, not to exceed 400mg/day. Patients will be seen every week up until Visit 4, and then will be seen every two weeks for the remainder of the study for assessment of efficacy and side effects.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Diagnosis of PTSD DSM-IV criteria

- No substance abuse/dependence for the previous 2 months (except for nicotine and


- Free of psychotropic medication, for 2 weeks (except 6 weeks for fluoxetine)

- Normal physical and laboratory examination (lab profile listed below)

- Negative urine screen for drugs of abuse

- Women of childbearing potential must be using nonpharmacologic medically approved

methods of birth control

- Signed informed consent

- Male or female, any race or ethic origin

Exclusion Criteria:

- Lifetime history of bipolar, psychotic, or cognitive disorders

- Suicidal, homicidal, or psychotic

- Diagnosis of bulimia or anorexia nervosa

- History of sensitivity to topiramate

- General medical conditions or ongoing treatment that contraindicate the use of

topiramate, such as seizure disorder or use of MAO inhibitors.

- Women planning to become pregnant or breastfeed during the study

Locations and Contacts

Tuscaloosa Research & Education Advancement Corporation, Tuscaloosa, Alabama 35404, United States
Additional Information

Related publications:

Berlant JL. Topiramate in posttraumatic stress disorder: preliminary clinical observations. J Clin Psychiatry. 2001;62 Suppl 17:60-3.

Starting date: July 2001
Last updated: July 28, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017